Colorectal cancer - Molecular Pathogenesis

Pathogenesis of Colorectal Cancer Introduction Colorectal cancer develops through a well-characterized progression from normal tissue to invasive malignancy. This process typically takes years and involves sequential accumulation of genetic and epigenetic changes in intestinal epithelial cells. Understanding this progression helps explain why early detection of precancerous lesions can prevent cancer, and why certain genetic mutations serve as markers for treatment response and prognosis. The Adenoma-Carcinoma Sequence The foundation of colorectal cancer pathogenesis is the adenoma-carcinoma sequence, which describes how normal epithelium transforms into invasive carcinoma through stepwise genetic changes. The progression begins with benign adenomatous polyps—these are the precancerous lesions that develop in the colon. Over time, these adenomas accumulate additional mutations and progress to carcinoma. This is crucial for understanding colorectal cancer prevention: screening programs specifically aim to detect and remove adenomas before they transform into cancer. The sequence typically follows a predictable pattern, though the exact timeline varies. A small adenoma may take years to develop further mutations, but once malignant transformation begins, the progression can accelerate. This is why the adenoma-carcinoma sequence provides such a valuable window for intervention. The Wnt Signaling Pathway and APC Gene Mutations The APC gene (Adenomatous Polyposis Coli) is the most frequently mutated gene in colorectal cancer, making it the initiating event in most adenoma-carcinoma sequences. How APC Normally Works To understand why APC mutation matters, you need to know about the Wnt signaling pathway. Under normal conditions, APC is part of a "destruction complex" that controls the protein β-catenin (beta-catenin). When the Wnt pathway is inactive, this complex phosphorylates β-catenin, marking it for degradation. This prevents β-catenin from accumulating in the cell. What Happens When APC Is Lost Loss of functional APC protein fundamentally breaks this control system: β-catenin accumulates in the cell instead of being degraded Excess β-catenin enters the nucleus In the nucleus, β-catenin binds to transcription factors and activates transcription of growth-promoting genes (proto-oncogenes) This leads to uncontrolled proliferation—the first step in cancer development This is why APC mutations are so commonly the initiating event: they remove the "brake" on a signaling pathway that promotes cell growth. Additional Mutations in the Wnt Pathway While APC is most common, other genes in the Wnt pathway can also be disrupted: β-catenin mutations (CTNNB1 gene): Mutations that prevent normal degradation of β-catenin itself have the same net effect as APC loss—β-catenin accumulation and uncontrolled signaling. Other pathway genes: Mutations in AXIN1, AXIN2, TCF7L2, and NKD1 also disrupt the destruction complex or the transcription machinery downstream, promoting tumor development through similar mechanisms. Progression Mutations: From Adenoma to Carcinoma After APC loss initiates the process, additional mutations drive the progression from small adenoma to carcinoma. The most important of these occur in predictable order: KRAS Activation KRAS is an oncogene that, when mutated, remains permanently in an active state, constantly sending "grow and divide" signals to the cell. KRAS activation typically follows APC loss and promotes uncontrolled cellular proliferation. This is a critical step in adenoma expansion. TP53 Inactivation The TP53 gene encodes the p53 tumor suppressor protein—often called the "guardian of the genome" because it normally: Checks for DNA damage Halts cell division if damage is detected Triggers apoptosis (cell death) in severely damaged cells Loss of functional p53 (through TP53 mutation) is a late event in the adenoma-carcinoma sequence and often marks the transition to invasive carcinoma. Without p53 function, cells can tolerate additional DNA damage and progress to malignancy. TP53 mutations indicate a more advanced lesion and worse prognosis. BRAF and PI3K Mutations Activating mutations in BRAF or PI3K are alternative mutations that can drive proliferation similar to KRAS activation. PTEN is a tumor suppressor that normally inhibits the PI3K pathway; loss of PTEN function removes this inhibition and promotes growth signaling. Chromosomal Instability Pathway Most sporadic colorectal cancers develop through the chromosomal instability (CIN) pathway, which involves gains and losses of entire chromosomes or large chromosomal segments. Think of this as a "big picture" genetic chaos: instead of point mutations changing single bases, the cell's chromosomes are shuffled, duplicated, or lost. This causes aneuploidy (abnormal chromosome numbers) and widespread gene dosage imbalances. The CIN pathway is the most common genetic route to colorectal cancer, present in the majority of cases. The mechanisms driving CIN include defects in chromosome segregation during mitosis and loss of checkpoint controls that normally prevent division with incorrect chromosome numbers. Mismatch Repair Deficiency and Microsatellite Instability A smaller but important subset of colorectal cancers (15-18%) develop through deficiency in mismatch repair (MMR) proteins. These proteins normally scan newly replicated DNA for errors and fix them. When MMR is defective, errors accumulate at an accelerated rate. Microsatellite Instability (MSI) A particularly detectable consequence of MMR deficiency is microsatellite instability (MSI). Microsatellites are short, repetitive DNA sequences (like ATATAT...). Without functional mismatch repair, these regions develop insertion or deletion errors at high frequency, creating a distinctive pattern that can be detected clinically. MSI colorectal cancers have important clinical implications: They often respond better to immunotherapy than non-MSI cancers They have different prognoses Testing for MSI status guides treatment selection Lynch Syndrome Lynch syndrome is an inherited cause of mismatch repair deficiency, accounting for approximately 3% of colorectal cancer cases. People with Lynch syndrome inherit a mutation in one of the MMR genes (like MLH1, MSH2, MSH6, or PMS2) and have dramatically elevated lifetime colorectal cancer risk. Epigenetic Alterations In addition to genetic mutations, colorectal cancers acquire epigenetic changes—heritable alterations in gene expression that don't involve changes to the DNA sequence itself. DNA Methylation Hypermethylation of CpG islands (regions rich in CG sequences) in the promoter regions of tumor suppressor genes is a key epigenetic alteration. This methylation silences gene expression, effectively turning off tumor suppressors without requiring a mutation. For example, methylation of the MLH1 promoter can silence the mismatch repair gene MLH1, mimicking the effect of inherited Lynch syndrome. Global hypomethylation is the opposite phenomenon: widespread loss of methylation across the genome. This can activate normally silenced genes and contribute to chromosomal instability. Histone Modifications Histone modifications (acetylation, methylation, and phosphorylation of histone proteins) alter how tightly DNA is packaged and regulate which genes are accessible for transcription. Aberrant histone modifications in colorectal cancer change which genes are expressed without altering DNA sequence. Field Defects and Field Cancerization A crucial concept in colorectal cancer is field defects (also called field cancerization)—widespread epigenetic or genetic changes in normal-appearing mucosa that create a predisposed microenvironment. Think of it this way: the same tissue that produced one cancer is at risk of producing more cancers because the entire "field" of tissue has acquired changes that promote malignant transformation. This explains why patients with one colorectal cancer are at increased risk for additional colorectal cancers. Field defects can be created by: Chronic inflammation Environmental exposures (like smoking or certain dietary factors) Inherited genetic susceptibility Accumulated aging-related epigenetic changes These widespread alterations interact with additional mutations in individual cells to promote tumor development. <extrainfo> Additional Tumor Suppressor Pathway Alterations SMAD mutations interrupt transforming growth factor-β (TGF-β) signaling in approximately half of colorectal cancers. TGF-β signaling normally acts as a growth inhibitor in epithelial cells; disruption of SMAD proteins removes this inhibition. DCC gene (Deleted in Colorectal Cancer) deletions or mutations contribute to tumor progression. DCC is involved in cell adhesion and apoptosis; loss of DCC promotes survival of abnormal cells. MicroRNA Dysregulation MicroRNAs (miRNAs) are small regulatory RNAs that control messenger RNA (mRNA) stability and translation. Global dysregulation of microRNA expression in colorectal tumors affects hundreds of target mRNAs, influencing proliferation, apoptosis, and differentiation. Consensus Molecular Subtypes Colorectal cancers can be classified into consensus molecular subtypes (CMSs) based on gene expression patterns. These subtypes include: CMS1 (Microsatellite instability immune): High MSI, strong immune activation CMS2 (Canonical): Chromosomal instability, good prognosis typically CMS3 (Metabolic): Metabolic reprogramming CMS4 (Mesenchymal): Poor prognosis, EMT activation Subtype classification informs therapeutic choices: for example, CMS1 tumors are more likely to respond to immunotherapy, while different subtypes may benefit from different targeted agents. This classification represents the future of precision oncology for colorectal cancer. </extrainfo> Integration: The Multi-Step Model The pathogenesis of colorectal cancer reflects the multi-step carcinogenesis model: cancer requires multiple mutations accumulated over time. The classical sequence is: APC loss → normal epithelium becomes adenoma KRAS activation → adenoma expands TP53 loss → malignant transformation Additional mutations → invasion and metastasis However, this is a generalization. Individual tumors may: Follow different mutational orders Develop through alternative pathways (like MMR deficiency) Acquire additional mutations between the canonical steps The key insight is that colorectal cancer is not a single disease but rather a group of diseases with different underlying genetic and epigenetic changes, which explains why different tumors respond differently to treatment and have different prognoses. Modern cancer management increasingly relies on identifying these underlying pathway alterations to guide therapy selection.